Registry of patients with congenital bleeding disorders and COVID-19 in Madrid
- PMID: 32524712
- PMCID: PMC7307027
- DOI: 10.1111/hae.14089
Registry of patients with congenital bleeding disorders and COVID-19 in Madrid
Abstract
Introduction: We present the first registry of patients with congenital bleeding disorders and COVID-19. The study has been carried out in the Community of Madrid, which has the highest number of cases in Spain. The objective is to understand the incidence of COVID-19, the course of the disease if it occurs and the psychosocial and occupational impact on this population.
Methods: We included 345 patients (246 of haemophilia, 69 of von Willebrand Disease, two rare bleeding disorders and 28 carriers of haemophilia). A telephone survey was used to collect the data.
Results: Forty-two patients presented symptoms suggestive of infection by COVID-19, and in six cases, the disease was confirmed by RT-PCR. The cumulative incidence of our series was 1.73%. It is worth noting the complexity of the management of COVID-19 in two patients on prophylaxis with non-factor replacement therapy. Adherence to the prescribed treatment was maintained by 95.5% of patients. Although 94% were independent for daily living activities, 42.4% had a recognized disability and 58% required assistance, provided by the Madrid Haemophilia Association (Ashemadrid) in 75% of cases. Only 4.4% of consultations were held in person.
Conclusions: Patients with congenital bleeding disorders infected with SARS-CoV-2 presented a mild course of the disease that did not require admission. Their identification and treatment by a specialist team from a Haemophilia Treatment Center are essential to make a correct assessment of the risk of haemorrhage/thrombosis. COVID-19 had a major impact on the psychosocial aspects of these patients which must be remedied with recovery plans.
Keywords: COVID-19; haemophilia A; rare bleeding disorders; telemedicine; von Willebrand disease.
© 2020 John Wiley & Sons Ltd.
Conflict of interest statement
Drs. Álvarez‐Román and Jiménez Yuste have participated as speakers, in advisory boards and sponsored symposia with Novo Nordisk, Takeda, Roche, Pfizer, Octapharma, Amgen, Novartis, CSL Behring and Sobi. Dr De la Corte and EC Rodríguez Merchán have participated as speaker in sponsored symposia with Pfizer and Takeda. García‐Barcenilla has participated as speaker and sponsored symposia by Novo Nordisk, Takeda, Roche, Pfizer, Novartis and Sobi, and in advisory boards with Novo Nordisk, Takeda, Roche, Pfizer, CSL Behring and Sobi. Monzón Manzano holds a predoctoral fellowship from Fundación Española de Trombosis y Hemostasia (FETH‐SETH). The rest of the authors have not conflict of interest to declare.
References
-
- Ministerio de Sanidad . Información Científica‐Técnica. Enfermedad por coronavirus. https://www.mscbs.gob.es/profesionales/saludPublica/ccayes/alertasActual.... Accessed April 17, 2020.
-
- World Federation of Haemophilia . COVID‐19 (coronavirus disease 2019) pandemic caused by SARS‐CoV‐2: practical recommendations for people with hemophilia. https://news.wfh.org/covid-19-coronavirus-disease-2019-pandemic-caused-b.... Accessed March 21, 2020.
-
- Ministerio de Sanidad . Procedimiento de actuación frente a casos de infección por el nuevo coronavirus SARS‐CoV‐2 del Ministerio de Sanidad. https://www.mscbs.gob.es. Accessed April 2020.
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
